Seeing Is Believing
Currently out of the existing stock ratings of Matthew Sharpe, 21 are a HOLD (42%), 3 are a SELL (6%), 26 are a BUY (52%).
Analyst Matthew Sharpe, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 86.67% that have a potential upside of 23.09% achieved within 255 days.
Matthew Sharpe’s has documented 116 price targets and ratings displayed on 12 stocks. The coverage is on Industrials, Technology sectors.
Most recent stock forecast was given on PL, Planet Labs PBC at 12-Jun-2023.
Analyst best performing recommendations are on MAXR (MAXAR TECHNOLOGIES).
The best stock recommendation documented was for MAXR (MAXAR TECHNOLOGIES) at 12/14/2022. The price target of $42 was fulfilled within 2 days with a profit of $17.96 (74.71%) receiving and performance score of 373.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 04-Nov-2024
$95
$16.17 (20.51%)
$190
2 months 14 days ago
(18-Dec-2025)
2/4 (50%)
$9.64 (11.29%)
72
Hold Since 02-Dec-2024
$93
$14.17 (17.98%)
$119
4 months 5 days ago
(27-Oct-2025)
4/9 (44.44%)
$7.69 (9.01%)
221
Hold Since 17-Oct-2025
$95
$16.17 (20.51%)
$105
4 months 5 days ago
(27-Oct-2025)
1/4 (25%)
$9.69 (11.36%)
74
Sell Since 28-May-2025
$80
$1.17 (1.48%)
$94
4 months 5 days ago
(27-Oct-2025)
3/4 (75%)
$-5.31 (-6.22%)
59
Sell Since 11-Dec-2024
$90
$11.17 (14.17%)
$122
4 months 5 days ago
(27-Oct-2025)
7/10 (70%)
$4.69 (5.50%)
72
What Year was the first public recommendation made by Matthew Sharpe?